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The antihyperglycemic action of metformin is based
on suppression of endogenous glucose production in
patients with type 2 diabetes. Metformin has been
used as a glucose-lowering agent in type 2 diabetes
since 1957, but was withdrawn from the United
States in 1975.1 This was largely due to the historical
experience of lactic acidosis with phenformin, another
biguanide. Lactic acidosis, characterized by the pres-
ence of metabolic acidosis and elevated lactate levels,
is a nonspecific end-stage consequence of a variety 
of serious disorders characterized by tissue hypoxia,
particularly conditions such as septicemia, renal or
hepatic failure. Lactic acidosis has also been reported
in patents treated with metformin; however, these
patients were mostly elderly and had multiple comor-
bidities. In contrast to the earlier biguanides, phen-
formin and buformin, which have a half-life of 7–12
hours, metformin has a half-life of only 1.5–5.0 hours,
is less lipophilic, does not accumulate in the liver and
is eliminated unchanged by glomerular filtration and
tubular secretion. In May 1995, metformin was
approved in the United States and rapidly gained wide
acceptance. The efficacy and benefits of metfomin
treatment in type 2 diabetes have been confirmed by
recent large-scale studies (United Kingdom Prospective
Diabetes Study) and endorsed by many consensus
statements.2,3 However, a large list of contraindications
may increase the incidence of lactic acidosis, which pre-
cludes millions of patients with type 2 diabetes from
taking metformin. Such contraindications include renal
impairment, cardiac insufficiency and old age, and
immediately receive intravenous contrast medium.
From the time when metformin was re-introduced
in the United States through to June 30, 1996, the
Food and Drug Administration has received reports of
lactic acidosis in 66 patients treated with this drug.4
In 47 patients, the diagnosis was confirmed on the
basis of circulating lactate values, in accordance with
established criteria for the diagnosis of lactic acidosis.
On the basis of the estimate that 1 million Americans
are taking metformin, the reported rate of confirmed
lactic acidosis should be about 5 cases per 100,000
patient-years. Of the 47 patients with confirmed diag-
nosis, 8 patients (17%) were older than 80 years. The
subsequently approved label stated that metformin
treatment should not be initiated in patients aged
> 80 years unless their creatinine clearance is normal.
A recent meta-analysis pooling data from 274 com-
parative trials and cohort studies revealed no cases of
fatal or nonfatal lactic acidosis in 59,321 patient-years
of metformin use or in 51,627 patient-years in the
non-metformin group.5 Using Poisson statistics, the
upper limit for the true incidence of lactic acidosis per
100,000 patient-years was 5.1 cases in the metformin
group and 5.8 cases in the non-metformin group.
There was no difference in lactate levels, either as mean
treatment levels or as a net change from baseline, for
metformin compared to non-metformin therapies.
Taken together, the available evidence indicates
that the incidence of lactic acidosis in type 2 diabetic
patients treated with metformin is similar to that in
patients who do not receive metformin. But old age
and other comorbidities could increase the risk of lac-
tic acidosis. The question arises as to whether old age
per se is a contraindication to the use of metformin. In
this issue of the Journal of the Chinese Medical Associa-
tion, Lin et al6 assessed fasting plasma lactate levels in
ambulatory elderly Taiwanese patients aged > 80 years
with type 2 diabetes taking metformin to identify inde-
pendent risk factors for hyperlactemia in these patients.
They recruited 66 elderly and 79 younger type 2 dia-
betes patients receiving metformin therapy. They
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found that plasma lactate concentrations in ambula-
tory elderly type 2 diabetic patients with metformin
therapy were not different from those in the younger
group. They concluded that old age per se should not
preclude prescription of metformin for the treatment
of type 2 diabetes.
Some studies of patients with type 2 diabetes,
including those over 70 years of age, have shown that
metformin treatment is not associated with signifi-
cantly increased plasma lactate levels.7 It is important
to point out that patients with contraindications were
excluded from many studies examining the effects of
metformin on plasma lactate. Dr Lin’s group presented
2 groups of type 2 diabetes patients with differences
not only in age but also in creatinine clearance rate,
and found that both groups had the same concentra-
tion of plasma lactate. Although there were some lim-
itations in their study, they have provided preliminary
data to show that old age per se cannot increase
plasma lactate in type 2 diabetes patients treated with
metformin.
Most patients with type 2 diabetes are over 65 years
old, and there is no evidence that old age should, in
itself, be a reason to withhold metformin. Metformin
is undoubtedly contraindicated in patients with severe
renal impairment. Evidence from meta-analyses sug-
gest that metformin can be used safely in chronic renal
insufficiency with a creatinine level up to 1.5 mg/dL.8
It must be borne in mind, however, that serum creati-
nine generally overestimates renal function, particu-
larly in the elderly and in those with reduced muscle
mass. Therefore, calculation of creatinine clearance
according to the method of Cockroft-Gault or esti-
mation of the glomerular filtration rate is preferable.
In conclusion, an estimated glomerular filtration
rate < 40 mL/min, but not old age per se, may be an
acceptable contraindication to the use of metformin.
Therefore, I suggest that metformin could be pre-
scribed for patients older than 80 years of age who have
normal renal function and no other contraindications.
References
1. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:
574–9.
2. UKPDS Group. Effect of intensive blood-glucose control with
metformin on complications in overweight patients with type 2
diabetes. United Kingdom Prospective Diabetes Study. Lancet
1998;352:854–65.
3. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR,
Sherwin R, Zinman B; American Diabetes Association; European
Association for Study of Diabetes. Medical management of
hyperglycemia in type 2 diabetes: a consensus algorithm for the
initiation and adjustment of therapy: a consensus statement of
the American Diabetes Association and the European Association
for the Study of Diabetes. Diabetes Care 2009;32:193–203.
4. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gabbi A,
Fleming GA. Lactic acidosis in patients with diabetes treated
with metformin. N Engl J Med 1998;338:265–6.
5. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of
fatal and nonfatal lactic acidosis with metformin use in type 2
diabetes mellitus. Cochrane Database Syst Rev 2006;CD002967.
DOI: 10.1002/14651858.CD002967.pub2.
6. Lin YC, Lin LY, Wang HF, Lin HD. Fasting plasma lactate con-
centrations in ambulatory elderly patients with type 2 diabetes
receiving metformin therapy: a retrospective cross-sectional study.
J Chin Med Assoc 2010;73:617–22.
7. Holstein A, Stumvoll M. Contraindications can damage your
health—is metformin a case in point? Diabetologia 2005;48:
2454–9.
8. Conolly V, Kesson CM. Metformin treatment in NIDDM
patients with mild renal impairment. Postgrad Med J 1996;72:
352–4.
J Chin Med Assoc • December 2010 • Vol 73 • No 12616
H.S. Chen
